Not exactly known for its dealmaking, Sarepta Therapeutics has thrown down a massive wad of cash to work with Arrowhead ...

ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Collaboration Deal with Sarepta Includes $825 Million Upon Closing On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced ...

H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the ...

Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas ...

In other recent news, Arrowhead Pharmaceuticals (NASDAQ:ARWR) has entered into a significant strategic partnership with Sarepta Therapeutics (NASDAQ:SRPT). The collaboration involves a $500 ...

In other recent news, Arrowhead Pharmaceuticals (NASDAQ:ARWR) has entered into a significant strategic partnership with Sarepta Therapeutics (NASDAQ:SRPT). The collaboration involves a $500 million ...

Sarepta has acquired the global rights to develop ARO-DUX4 and ARO-DM1, two RNAi therapeutic candidates for types of muscular ...

The revision follows Sarepta's announcement of a major collaboration with Arrowhead Pharmaceuticals (NASDAQ:ARWR) that significantly expands its product pipeline. Sarepta Therapeutics disclosed its ...

The revised price target reflects the current valuation following the deal with Sarepta Therapeutics. In other recent news, Arrowhead Pharmaceuticals (NASDAQ:ARWR) has made significant strides in its ...